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ABSTRACT: The massive amount of human genetic informa-
tion already available has accelerated the identification of target
genes, making gene and nucleic acid therapy the next generation
of medicine. Nanoparticle (NP)-based anticancer gene therapy
treatment has received significant interest in this evolving field.
Recent advances in vector technology have improved gene
transfection efficiencies of nonviral vectors to a level similar to
viruses. This review serves as an introduction to surface
modifications of NPs based on polymeric structural improve-
ments and target moieties. A discussion regarding the future
perspective of multifunctional NPs in cancer therapy is also
included.
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1. INTRODUCTION
With the morbidity rate increasing over the past few decades,
malignant tumors have become the biggest threat to human
health. More than 200 different types of cancers have been
discovered. More than 10 million cases were diagnosed, and
over 7 million people died from cancer in 2008.1 Conventional
cancer therapies, including chemotherapy and radiotherapy, are
limited by their inability to distinguish malignant from
noncancerous organs and tissues. The toxicity of chemotherapy
often results in serious side effects accompanied by drug
resistance. Modern therapy has been trending toward
customized treatments that require high efficiency, specific
targeted delivery, and minimal side effects for advanced cancer
therapy. Various drug delivery systems, such as liposomes,
micelles, vesicles, and nanoparticles, have been developed to
improve the bioavailability of chemodrugs and to fulfill efficient
drug delivery (Figure 1). The current desires in cancer therapy
can be satisfied through the development of new drug delivery
systems. With advances in molecular biology and biotechnology
as well as the completion of the human genome project, it has
been realized that most cancers are caused by genetic
mutations, which has given rise to a growing list of genetic
disease targets and gene therapy as a potential approach to
cancer treatment.
Gene therapy can be defined as the treatment of human
disease using the transfer of genetic materials into specific cells
of the patient.2 In cancer therapy, the delivered genes can be
used in different approaches, such as mutation correction,
enhancement of the immune response against tumor cells,3
RNA interference,4 antiangiogenesis, and the production of
cytotoxic proteins or prodrug-activating enzymes. Prodrug-
activating enzymes alter the expression of existing genes,
facilitating a desired cellular or tissue response. Because gene
therapy involves the intracellular transfer of nucleic acid drugs,
most of them are vulnerable to nucleases, which makes
traditional carriers incapable of achieving the expected
biological effects. Numerous obstacles emerge during the
transportation of the drugs from the site of administration to
localization in the cell nucleus. These obstacles include the
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Figure 1. Various drug delivery systems for drug and gene delivery.
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physical and chemical stability of DNA, the extracellular,
cellular, and intracellular biological membranes, uptake by
endocytosis, and the necessary escape from endosomal and
nuclear localization. Generally, there are two different
categories of gene transferring methods depending on the
nature of the carrier: gene transfer mediated by viruses and
nonviral gene delivery using artificial carriers. While viral
vectors are able to mediate gene transfer with high efficiency
and long-term gene expression, there are also several
limitations. Viral vectors give rise to serious safety concerns,
including limit in the size of carried gene, vector antigenicity,
inflammation induced by the vector, and possible insertional
mutagenesis. Viral vectors are also difficult to produce on a
large scale. Nonviral vectors as alternative gene transfer vehicles
also have benefits, including a lack of immunogenicity, low
toxicity, and potential specific tissue targets.5 However, the
gene transfer efficiency of the nonviral vectors has been far
below that of the viral vectors.
Ideally, a gene delivery system should be stable, biocompat-
ible, nontoxic, and capable of high transfection efficiency with
specificity. Among the various nonviral gene carriers, nano-
particles (NPs) are an ideal platform that incorporates all
desirable characteristics into a single gene delivery system.
Their nanometer size allows for more efficient vector
penetration into the target tissue. NPs also provide unlimited
DNA packaging capacity, well-defined physicochemical proper-
ties, and a high degree of molecular diversity that allows
extensive modifications to overcome extracellular and intra-
cellular barriers.
In this paper, we focus on the factors for novel multifunc-
tional NPs, specifically design, and illustrate their potential
application for cancer therapy. The current limitations and
toxicological risks are also discussed.
2. DEFINITION OF MULTIFUNCTIONAL NPS FOR
GENE THERAPY
Nanotechnology refers to the creation and application of
materials at the nanometer scale. Nanodevices have experienced
significant development and improvement since the emergence
of nanotechnology. They are being used in a wide array of fields
ranging from electronics and communications to chemistry,
energy, and biology. Nanomedicine combines nanotechnology
with healthcare and has significant promise for medical
treatments and therapies in certain areas, such as imaging,
faster diagnosis, drug delivery, tissue regeneration, and the
development of new medical products. Several NPs are already
approved for clinical use, and numerous products are being
evaluated in clinical trials.6
Multifunctional NPs combine different functionalities into a
single stable construct, which can codeliver multiple
components with high delivery efficiency and realize therapy
and diagnosis simultaneously. For example, a core particle
could be linked to a specific targeting function to recognize the
unique surface signatures of their target cells or be modified
with an imaging agent to monitor the drug transport process.
Ideally, the vectors appropriate for gene delivery should
possess the following merits. First, the vectors have to compact
genetic material into particles and protect them from
degradation and undesired interactions with the biological
environment. Second, the vectors have to be capable of
overcoming the extracellular and intracellular barriers to
transfer the molecules into the target cells, e.g., endosomal
escape and localizing in the nucleus. Third, the vectors should
have very little to no toxicity and avoid stimulating the immune
system. Other than these properties, the vectors should also be
biodegradable and able to induce sustained expression with
high transfection efficiency over a defined period of time.
3. DESIGN AND FABRICATION OF GENE
LOADED-MULTIFUNCTIONAL NPS FOR CANCER
THERAPY
The design of a highly efficient multifunctional NP that meets
all of the above requirements in a single carrier is an elaborate
process that requires multiple steps. First, various functional
units are synthesized. These functional units are then
procedurally assembled using supramolecular assembly tech-
nologies into a nanosystem with a suitable size, controllable
structure, and good biocompatibility. The supporting NP cores
are mainly modified with biocompatible materials to stabilize
the NP and different linkers to achieve target specific delivery.
NPs can be made from a variety of materials, such as
compositing polymers, lipids, proteins, metals, or semi-
conductors with well-defined shapes. NPs can be designed
and synthesized using top-down or bottom-up engineering
techniques.7,8 The current nanocarrier platforms targeting
tumors can be classified into three major categories: organic
vectors (e.g., lipid-based NPs and polymer-based NPs),
inorganic vectors (e.g., magnetic NPs, gold NPs, and quantum
dots) and hybrid vectors (e.g., theranostic NPs that contain
both organic and inorganic materials). We list some examples
of currently available NP platforms for tumors in Table 1.
Although nonviral carriers have many advantages, they
nonetheless possess some problems, such as low intracellular
gene-transferring efficiencies and transient gene expression.
Polymer-based gene delivery systems have attracted significant
attention as a means of addressing specificity toward the target
cells and the capacity of gene transduction. Among the various
polymer materials, the most frequently used strategy is
incorporating DNA into condensed particles based on cationic
lipids or cationic polymers.18 Under certain conditions, cationic
Table 1. Examples of NP Platforms for Tumor Gene
Delivery
materials type of NPs main component main applications ref
organic liposomes DSPE,a protein drug carrier 9
micelles PEO-b-PCL drug carrier 10
polymer NPs Pluronic F127/
PEI
drug carrier 11
dendrimers CMCht/PAMAM drug carrier 12
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polymers containing several positively charged amine groups in
their backbone will interact with negatively charged DNA,
leading to the self-assembling and condensing of DNA or RNA
into compact NPs. The compact structure of the charge-
neutralized core provides excellent protection of the enclosed
nucleic acid drugs from nucleases. Once the genes have been
wrapped up by polycations, the cores should maintain their
stability, allowing for facile cellular uptake and localization
inside the cell. Thus, these vectors should inevitably surpass the
numerous obstacles encountered from the site of admin-
istration to the final localization in the cell nucleus.19 This result
means that the carriers should possess efficient gene delivery
capacities.
3.1. The Design of Supporting Polymeric Nanocores.
To date, polyethylenimine (PEI),20,21 poly L-lysine (PLL),22
chitosan,23,24 poly(2-N-(dimethylaminoethyl) methacrylate)
(pDMAEMA),22,25 and poly(amidoamine) (PAMAM)26,27 are
the most frequently used polycations (Figure 2). PLLs can
interact with negatively charged DNA through electrostatic
forces but with inefficient endosomal escape and transfection.
PLL is relatively cytotoxic. Although they are not biodegrad-
able, PEI and PAMAM can mediate endosomal disruption via
the proton sponge effect.28 Chitosan is a linear biodegradable
polycation, but its application is limited due to its limited
transfection efficiency. Among these polymers, PEI is the most
studied material due to its strong buffering range from 5.1 to
7.4 along with its high binding capability toward DNA and
relatively high transfection efficiency. The primary, secondary,
and tertiary amines in the structure of PEI may influence the
DNA binding and toxicity. High molecular weight PEIs
(branched, 25 kDa) are regarded as the gold standard of
gene transfection but often have high toxicities. Low molecular
weight (LMW) PEIs (MW < 2000) may be an alternative to
reduce toxicity, but they are not satisfactory gene vectors due to
their limited efficiency.
Various modifications have been explored to improve gene
delivery efficacy. Polymers are chosen and designed to address
one of the perceived barriers during the gene delivery process
for the purpose of effective transfection, reduced toxicity, and
increased biocompatibility.29,30 Hydrophobic/hydrophilic mod-
ifications and the proton sponge effect are the basic strategies
for achieving a balance between gene delivery efficacy and
toxicity. These strategies help address the key factors involved
in gene delivery, such as DNA compacting, cell surface binding
and uptake, endosomal and lysosomal escape, localization in
the nucleus, and vector unpacking. Therefore, modifications
should affect most of the steps involved in the entire gene
delivery process.
The modification of the periphery of PEI will enhance the
stability of the polyplex. The introduction of hydroxyl groups
can markedly improve the serum-tolerant capacity. PEGylation
is the most utilized method and creates a hydrophilic exterior
that reduces nonspecific interactions with serum components
and clearance by phagocytic systems. This method is best
known as the stealth effect. However, the “PEG dilemma”, the
crucial issue caused by the use of PEG, also reduces gene
expression by decreasing the surface charges of the copolymers,
which results in disadvantages in terms of controlling
intracellular trafficking of cellular uptake and endosomal
escape.31,32 A series of PEI derivatives, obtained by treating
PEI 25 kDa with tris(hydroxymethyl)acrylamidomethane
(THA) via the Michael addition,33 are called PEI-g-THAn
(PTns, where n represents the average THA units per PEI
molecule). The PTns show lower cytotoxicity and better serum-
resistant capacity than PEI25 kDa. Specifically, the transfection
efficiency of PT26/DNA is 29-fold higher than that of PEI25
kDa in HeLa cells in serum-containing medium. In vitro flow
cytometry analysis shows that the PTns can efficiently mediate
the nucleic acids located in the cell. Xiao et al. reported a
bioreducible PEI-based/p65 shRNA complex NP used for the
treatment of breast cancer.34 In this system, Tween 85
improves the stability of complex NPs in the circulation system
and increases cellular uptake by interacting with low-density
lipoprotein receptors. The introduction of a disulfide bond
guarantees the rapid release of shRNA due to the high
concentration of glutathione in the intracellular tumor
environment.
Hydrophobic segments that are conjugated to polycations
may influence the steps in gene delivery by some of the
following mechanisms: (i) increasing the physical encapsulation
of genetic materials, (ii) promoting complex charge inversion,
(iii) enhancing adsorption to the cell membrane, (iv) alleviating
serum inhibition, (v) facilitating gene dissociation from
polycation carriers, and (vi) reducing toxicity. Liu et al.
reviewed several hydrophobic molecules for PEI modification
in 2010,35 including linear alkyl chains of fatty acids (acetate,
butanoate, hexanoate, butyric anhydrides, myristate, etc.),
conjugates of Pluronic (PPO-PEO and Pluronic-123), and
cyclic hydrophobic molecules (cholesteryl chloroformate,
aldehyde PEG-cholesterol ether, and dexamethasone mesylate).
These modifications are mainly based on the principles that
acylation reduces the basicity and availability of free amine
groups and the steric hindrance of PEI.36,37
An effective way to hydrolytically or reductively form
degradable PEI polymers is through coupling of low molecular
weight PEIs. Xun et al. modified PEI 600 with polyesters.38
Briefly, linear biodegradable polyesters with carbon−carbon
double bonds were prepared and subsequently appended with
Figure 2. Chemical structures of polycations.
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PEI 600. Agarose gel retardation and fluorescence quenching
assays showed that DNA was completely retarded by these
materials at a weight ratio of 0.8. The resulting polyplex sizes
were approximately 275 nm, and the zeta-potential values were
about +20−35 mV. An MTT assay suggested that the
cytotoxicity of these polymers was much lower than that of
25 kDa PEI. In vitro transfection toward 7402, HEK293, and U-
2OS cells showed that these novel vectors exhibited much
higher transfection efficiencies when compared to 25 kDa PEI,
especially in U-2OS cells. The results suggest that biodegrad-
able ester bonds ensure better biocompatibility and lower
cytotoxicity. Several cationic polymers derived from PEI 600
linked with poly(amino alcohol esters) have also been
introduced as promising nonviral biodegradable vectors.39
Three polymers were prepared by linking PEI 600 with
diglycidyl adipate (DA-PEI), diglycidyl succinate (DS-PEI), and
diglycidyl oxalate (DO-PEI), respectively. These polymers
exhibited good DNA condensing ability with a size of 120−250
nm and zeta-potentials around +10−20 mV, while the weight
ratio (polymer/DNA) was from 0.5 to 32. Agarose gel
retardation showed that DNA could be released from the
polyplexes after being preincubated for 30 h. In vitro
experiments found that DS-PEI (weight ratio of 1) showed
transfection efficiency approximately 5 times higher than the
PEI in A549 cells. Meanwhile, the cytotoxicity of these three
diglycidyl PEIs assayed using MTT is lower than that of 25 kDa
PEI in HEK293 cells.
Adding low molecular weight PEIs onto biocompatible
polymers can significantly improve the biocompatibility of PEIs.
The most frequently used polymers include cyclodextrin,40−43
chistosan,44−46 polycarbonate,47 and dextrans.48,49 These
materials are excellent candidates for PEI modification due to
their biocompatibility, biodegradability, and low toxicity. The
amphipathic PEIs also play an important role in gene
transfection. Amphipathic deoxycholic acid (DA)-modified
polyethylenimine (PEI 1.8) (DA-PEI 1.8) was found to have
a high membrane permeability, enhancing both cellular
internalization and target gene silencing.50 This PEI has been
conjugated with hydrophobic polylactide (PLA) to form
amphiphilic PEI for the construction of NPs.51 PEI-PCL
(polycaprolactone) uses amphiphilic diblock copolymers, which
assemble as biodegradable nanocarriers for codelivery of BCL-2
siRNA and doxorubicin (DOX) and modified with folic acid as
the targeted unit.52 A series of experiments showed that the
hierarchical nanoassembly platform was effective for siRNA and
hydrophobic drug codelivery. Furthermore, in vivo transfection
was observed using an in situ rat C6 glioma model, and the
animal study showed that the folate-targeted PEI-PCL
multifunctional nanoparticles could inhibit tumor growth and
prolong the rat survival time.53
3.2. The Specific Design Strategies of Nanocarriers for
Cancer Therapy. The complexity of tumorigenesis, the
heterogeneity of cancer cells, and various physiological barriers
have been the biggest obstacles in cancer therapy. Micro-
environment changes around the tumor cells are complicated.
Changes such as increased interstitial fluid pressure caused by
leaky vasculature, increased acidity among tumors, poor
lymphatic drainage, and a high density of stroma and cells
significantly impede drug penetration and gradually induce drug
resistance. Additionally, most cancers are caused by gene
mutations or loss of function. Therefore, the combined delivery
of drugs and genes has emerged as an exciting method for
treating cancer. Combined delivery possesses a synergistic effect
that can increase drug efficacy or enhance gene transfection
efficiency. However, one of the most important challenges for
highly efficient delivery is the specificity of the delivery systems.
Thus, targeting moieties on the surface of a nanosystem have
been developed to meet these limitations.
The mechanism for NP targeting can be either passive or
active (Figure 3). Most NPs are expected to accumulate in
tumors due to incomplete tumor vasculature. Tumors also tend
to retain compounds, especially macromolecules, more than
normal tissues. These pathophysiologic characteristics contrib-
ute to the enhanced permeability and retention effect54−56 and
form the basis of passive targeting. However, passive targeting
suffers from several limitations, e.g., the PEG dilemma.
Attaching specific moieties on the NP surfaces can effectively
improve the binding affinity toward target cells and help
overcome these limitations. The targeting moieties can be
classified as therapeutic agents, diagnostic agents, or barrier-
avoiding agents according to their functions. These materials
can also be categorized by their composition, i.e., proteins
(mainly antibodies and their fragments), peptides, aptamers,
small molecules, or others (vitamins or carbohydrates).
Multiple gene mutations or abnormalities of gene expression
can lead to the development of tumors. To effectively treat the
broad spectrum of gene mutations and abnormalities, different
gene therapy approaches are used. Some examples of these are
mutation correction, immune response enhancement, RNA
interference, targeted lysis of tumor cells using selective
replicative viruses, antiangiogenesis, suicide gene transfer, and
bone marrow protection using drug resistance genes.57,58 Each
type of cancer has its own specific characteristics. For example,
the brain is protected by the blood−brain barrier (BBB), which
provides a barrier for brain tumors, referring to a heterogeneous
group of primary and metastatic neoplasms in the central
nervous system. The BBB is composed of tight junctions
between endothelial cells, pericytes, abasement membrane, and
the feet of astrocytes. Additionally, the ATP-binding cassette
transporters, such as P-glycoprotein, are highly expressed in the
brain. Additionally, the blood−cerebrospinal fluid barrier and
the blood−tumor barrier act as a second and third barrier,
respectively. Therefore, targeted design in gene delivery should
take these factors into consideration.
Prostate stem cell antigen (PSCA) is a prostate-specific
glycosyl phosphatidylinositol-anchored glycoprotein, which can
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be used for prostate cancer targeted imaging and therapy.59,60
In approximately 25% of non-small-cell lung cancer patients, c-
Met, and the hepatocyte growth factor (HGF) receptor, were
abundantly expressed. Wu et al. site-direct conjugated anti-c-
Met antibody via cystine residues with liposomal and dual
targeting properties. The inhibition of tumor growth and
prevention of angiogenesis were observed for c-Met expression
in angiogenic endothelium and tumor cells.61,62 Chlorotoxin
(CLTx) is a 36 amino acid peptide, which can permeate intact
BBB and has a strong affinity for tumors of neuroectodermal
origin.63 Zhang et al. developed an in vivo brain tumor targeting
magnetic/optical nanoprobe based on CLTx. In vivo MRI
contrast enhancement and optical imaging were used for
evaluation and found that this multifunctional platform may be
further developed for brain tumor targeted therapeutic NP
systems.64 Tumor-associated underglycosylated mucin-1
(uMUC-1) antigen is overexpressed in more than 90% of
breast cancers. Medarova et al. have bound nanodrugs with
uMUC-1 targeting EPPT synthetic peptides for selective breast
tumor targeting.65,66 HER-2 is another overexpressed gene
commonly found in some tumors, such as breast and ovarian.
Herceptin (HER), a monoclonal antibody able to selectively
recognize HER-2, was used by Mattu et al. as the targeting unit
when modifying biodegradable NPs through hydrophilic/
hydrophobic interactions for breast cancer therapy.67 Due to
differing gene expression levels in various types of breast cancer
cells, Chen et al. utilized HER in a different approach. They
prepared PEO-b-PγMPS-coated magnetic iron oxide NPs
(IONPs) before further conjugating HER or a single chain
fragment (ScFv) of an antibody against epidermal growth factor
receptor to PEO-b-PγMPS-coated IONPs. These two types of
NPs could bind specifically to different types of breast cancer
cells and enable active receptor-targeted imaging of xenografted
breast tumors in nude mice using MRI.68
3.3. Other Factors That Influence the Therapeutic
Effectiveness of Multifunctional NPs. Efforts have been
made to develop less toxic and more biodegradable materials
for vectors. Targeting moieties have been added to the surface
of NPs for tumor cell recognition. Studies have revealed that
some properties of NPs, such as the small size, large surface
area, and geometry, could be partially responsible for their
potential hazard to human health. Because of these factors, the
size and concentration should be carefully controlled according
to the NP platform. Several studies have reported that there is
an inverse relationship between quantum dot size and
concentration and the adverse effects of NPs: smaller sizes
and higher concentrations are more cytotoxic.69,70 Geometry
also influences the NP toxicity, especially in carbon nanoma-
terials, with single-walled nanotubes being the most toxic and
nano-60 fullerenes the least toxic.71,72 Unfortunately, surface
modification also seems to have a role in the cytotoxicity.
Studies with quantum dots and gold NPs have indicated that
toxicity varies depending on the nature of the surface coating
applied to the NP.72−74
Not only do variations in NP characteristics induce toxicity
but the density of non-biofouling moieties and targeting ligands
on the surfaces of NPs can also influence their efficacy.56
Shielding materials, such as PEG and polysaccharide dextrans,
provide a steric barrier that prevents nonspecific protein
absorption and modifies the surface properties of the NPs to
avoid recognition based on the RES.75 Few studies have
reported that targeting ligands on the surface of NPs must be
present at concentrations that exceed a minimum threshold for
effective binding.76 In contrast, some studies insist that high
ligand densities can promote nonspecific interactions with
endothelial and other noncancerous cells, which increases
immunogenicity, thereby causing opsonization-mediated clear-
ance of the NPs.77 Therefore, the optimization of the density of
the modification moieties plays a critical role in NP fabrication.
4. CONCLUSIONS AND FUTURE PERSPECTIVES
The advantages provided by NPs have led to an accelerated
development of gene therapy for cancer in the past decades.
The emergence of various biocompatible materials and the
development of gene technology have deepened our under-
standing and enabled us to develop multifunctional NPs for
tumor diagnosis and therapy. The ultimate goal of multifunc-
tional NPs is to enhance patient survival and improve quality of
life, especially for multidrug resistance patients. The materials
chosen as vectors, preparation methods, and modification
strategies should all be taken into consideration when
attempting to achieve the maximization of the therapeutic
efficacy in a NP system. Despite enormous efforts, multifunc-
tional NPs have not yet met the standard requirements to
achieve clinical significance.
Currently, the codelivery of genes and chemotherapeutics
has been proposed as an exciting method for treating cancer.
This method possesses a synergistic effect that can increase
drug efficacy or enhance gene transfection, which in turn
increases the efficiency of cancer treatment and prolongs the
survival time of cancer patients. A similar concept, hybrid NPs,
has been introduced and rapidly developed. Hybrid NPs
combine different NP platforms into one system as a potential
theranostic platform. This platform offers noninvasive visual-
ization of drug distribution and accumulation at target sites,
real-time monitoring of therapeutic responses, and individu-
alized dosing regimens.78−80 Theranostic systems usually
combine MRI and optical imaging with therapeutics. The
high-resolution image can help accurately determine a clear
tumor boundary by eye and recognize the pseudoprogression
after radiotherapy and antiangiogenesis therapies.81,82 Thera-
nostic NPs will open even more opportunities to create
innovative NPs for tumor therapy.
Apoptosis, or programmed cell death, is widely associated
with its important role in cancer therapy.83 Therefore, many
novel approaches for successful treatment of cancers have been
established through targeted pro-apoptotic therapeutic proto-
cols and the development of apoptosis-inducing drugs that
target the tumor without causing severe impairment to the
normal tissue.84 The genes for clinical cancer therapy that
target apoptotic machinery mainly include TNF-α, TRAIL,
caspase-9, Bik, Bcl-2, and XIAP. The apoptotic machinery can
be targeted via the introduction of a gene encoding an inducer,
mediator, or executioner of apoptotic cell death or by inhibiting
antiapoptotic gene expression. These methods have significant
potential for efficient and specific gene delivery and
administration systems.
The evaluation of risks associated with exposure to NPs is
not well studied, and the present results are inconclusive. It has
been suggested that NPs affect biological behaviors at the
cellular, subcellular, protein, and gene levels, but other claims
indicate that NPs are biologically inert materials and therefore
are safe for in vivo application. Nanotoxicology has emerged to
investigate the safety of nanotechnologies, but only limited
statistics have been obtained so far. The regulatory issues
surrounding NPs are often unclear and difficult to navigate,
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adding another hindrance to the field of nanotoxicology. The
inherent complexity of NP systems establishes a need for
specific regulations and official guidelines.71,85,86
The unique properties of multifunctional NPs allow for the
selection of the best possible combination of factors for
maximum effectiveness. There is still a long way to go before
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